Sangamo Therapeutics (SGMOQ) Change in Receivables (2010 - 2025)

Sangamo Therapeutics' Change in Receivables history runs 16 years deep, the most recent figure standing at -$152000.0 for Q4 2025.

• On a quarterly basis, Change in Receivables rose 98.48% year-over-year to -$152000.0 in Q4 2025; TTM through Dec 2025 was -$155000.0, a 60.96% increase from a year earlier, with the FY2025 full-year figure at -$155000.0, up 60.96% from the prior year.
• Change in Receivables retreated to -$152000.0 in Q4 2025 per SGMOQ's latest filing, from $151000.0 in the prior quarter.
• Across five years, Change in Receivables topped out at $9.9 million in Q3 2024 and bottomed at -$10.0 million in Q4 2024.
• The 5-year median for Change in Receivables is -$156000.0 (2025), against an average of -$242650.0.
• Biggest YoY gain for Change in Receivables was 732.33% in 2024; the steepest drop was 4331.11% in 2024.
• Year by year, Change in Receivables stood at -$2.0 million in 2021, then jumped by 56.81% to -$844000.0 in 2022, then surged by 73.34% to -$225000.0 in 2023, then slumped by 4331.11% to -$10.0 million in 2024, then soared by 98.48% to -$152000.0 in 2025.
• Per Business Quant, the three latest SGMOQ Change in Receivables figures stand at -$152000.0 (Q4 2025), $151000.0 (Q3 2025), and $6000.0 (Q2 2025).